306 related articles for article (PubMed ID: 22166424)
1. Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.
Béraud D; Maguire-Zeiss KA
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1(0 1):S17-20. PubMed ID: 22166424
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.
Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
4. Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.
Watson MB; Richter F; Lee SK; Gabby L; Wu J; Masliah E; Effros RB; Chesselet MF
Exp Neurol; 2012 Oct; 237(2):318-34. PubMed ID: 22750327
[TBL] [Abstract][Full Text] [Related]
5. Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets?
Jiang TF; Chen SD
Neurosci Bull; 2012 Oct; 28(5):649-57. PubMed ID: 22961477
[TBL] [Abstract][Full Text] [Related]
6. The role of Toll-like receptors and neuroinflammation in Parkinson's disease.
Heidari A; Yazdanpanah N; Rezaei N
J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422
[TBL] [Abstract][Full Text] [Related]
7. [Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease].
Qiao S; Luo JH; Jin JH
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Mar; 41(2):210-4. PubMed ID: 22499522
[TBL] [Abstract][Full Text] [Related]
8. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
[TBL] [Abstract][Full Text] [Related]
9. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
10. The central theme of Parkinson's disease: α-synuclein.
Ozansoy M; Başak AN
Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
[TBL] [Abstract][Full Text] [Related]
11. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease and α-synuclein expression.
Devine MJ; Gwinn K; Singleton A; Hardy J
Mov Disord; 2011 Oct; 26(12):2160-8. PubMed ID: 21887711
[TBL] [Abstract][Full Text] [Related]
13. alpha-Synuclein: a therapeutic target for Parkinson's disease?
Maguire-Zeiss KA
Pharmacol Res; 2008; 58(5-6):271-80. PubMed ID: 18840530
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas9 Gene Editing Protects from the A53T-SNCA Overexpression-Induced Pathology of Parkinson's Disease
Yoon HH; Ye S; Lim S; Jo A; Lee H; Hong F; Lee SE; Oh SJ; Kim NR; Kim K; Kim BJ; Kim H; Lee CJ; Nam MH; Hur JW; Jeon SR
CRISPR J; 2022 Feb; 5(1):95-108. PubMed ID: 35191750
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptors and their therapeutic potential in Parkinson's disease and α-synucleinopathies.
Kouli A; Horne CB; Williams-Gray CH
Brain Behav Immun; 2019 Oct; 81():41-51. PubMed ID: 31271873
[TBL] [Abstract][Full Text] [Related]
16. Modulation of alpha-synuclein aggregation by dopamine: a review.
Leong SL; Cappai R; Barnham KJ; Pham CL
Neurochem Res; 2009 Oct; 34(10):1838-46. PubMed ID: 19444607
[TBL] [Abstract][Full Text] [Related]
17. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
20. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
